Home/Pipeline/Biosimilar Adalimumab (Abrilada®)

Biosimilar Adalimumab (Abrilada®)

Chronic Inflammatory Diseases (e.g., RA, Psoriasis)

LaunchedMarketed (US)N/A

Key Facts

Indication
Chronic Inflammatory Diseases (e.g., RA, Psoriasis)
Phase
Launched
Status
Marketed (US)
Company

About Viatris

Viatris is a mission-driven global healthcare company formed in 2020 to empower people worldwide to live healthier lives through expanded access to medicines. Its strategy is built on four complementary pillars—generics, complex generics, biosimilars, and established brands—enabling it to deliver a broad portfolio across therapeutic areas and economic spectrums. The company has established itself as a leader in biosimilars and complex generics, managing a significant pipeline of 247 candidates while executing a strategic transformation to optimize its portfolio and drive sustainable growth through 2030.

View full company profile